Introduction
Although pulmonary arterial hypertension (PAH) is a devastating disease with high mortality despite advanced therapies 1, 2 , a subset of patients characterized by acute vasodilator responsiveness has excellent survival 3 . Patients who have an acute drop in mean pulmonary artery pressure of at least 10mmHg to less than 40mmHg with preserved cardiac output in response to vasodilators such as inhaled nitric oxide are defined as having vasodilator-responsive PAH (VR-PAH) and their survival is measured in decades as opposed to months for nonresponsive PAH patients (VN-PAH) 3 . Moreover, VR-PAH patients can be safely treated with calcium channel blocker therapy as opposed to more expensive medications 4 .
VR-PAH is an infrequent sub-phenotype of PAH and most commonly found in patients with idiopathic PAH 3, 5 . Patients with VR-PAH are identified at the time of diagnostic right heart catheterization (RHC) during acute challenge with vasodilators such as nitric oxide, adenosine and prostacyclin 6 . It has been noted that a positive vasodilator response can be elicited with many vasodilators such as nitric oxide, adenosine, hydralazine and calcium channel blockers. The multiple pathways that these drugs affect suggest an underlying, but as yet unidentified mechanism that is shared among VR-PAH patients. Identification of molecular markers associated with VR-PAH may provide insight into disease mechanism or serve as biomarkers of this important sub-phenotype of PAH.
We hypothesized that VR-PAH has a different molecular signature than VN-PAH and that this difference can be exploited to differentiate VR-PAH using peripheral blood samples. To test this hypothesis we performed microarray on cultured lymphocytes from VR-PAH and VN-PAH and identified the genes that displayed the greatest intergroup differences in expression.
We confirmed the differences using whole blood-isolated RNA. We developed a PCR-based VR-PAH is an infrequent sub-phenotype of PAH and most commonly fou ou und nd d in n n pa pa pati ti tien en e t ts f with idiopathic PAH 3, 5 . Patients with VR-PAH are identified at the time of diagnostic right he ear ar art t t ca ca cath th thet et eter er rizat at tio io ion n (RHC) during acute challen n nge ge g with vasodilat at tor o s su su uc ch ch as nitric oxide, ad den n enosine and d pr pr ros sta ac cy cycl cl clin in in 6 6 6 . . It It It h has as as b b bee ee en n not te ed d d tha a at a a p pos os osit itiv iv ve e va vaso sodi dila lat t tor r re resp sp spon onse se e c c can an a be e e l el elic i i i i ited wi wi ith th th m m man any y y va va vaso sod d dil la ato tor r rs s suc uch h as as n n nit it itri ri ric c ox ox oxid id ide e e, , ad ad den en enos os sin i e e, e h h hyd yd ydra a ala la l z z zine ne ne a an n nd c cal alci ci c um um um c c cha h hann n nel l l blockers. Th he e mu mu m lt lt ltip ip ple le e p p pat thw hw hway ay ays s s th th t at at a the he hese se se d d dr r rug ug ugs s s af af a fe fe fect t s s sug ug ugge ge g st st st a a an un un unde de derl rl rlyi yi ying ng ng, , bu bu but t as as as yet r r prediction tool and validated it in the peripheral blood of an independent validation cohort of VR-PAH.
Methods
Approval was obtained from the Vanderbilt University Intuitional Review Board (protocol 9401) and written informed consent was obtained from all research subjects. As part of this protocol, all patients with PAH were offered enrollment into the Vanderbilt Pulmonary Hypertension
Research Cohort (VPHRC) as previously described 7 . Patients were generally enrolled within one year of their fist visit at Vanderbilt University Medical Center. This cohort is enriched in heritable PAH and family members were enrolled at the time of their referral to our cohort as previously described 8 . In these experiments only idiopathic and heritable PAH patients with available, high-quality peripheral blood lymphocytes and/or high quality RNA samples were included for analysis. Healthy controls were free from known cardiovascular disease (n=22 9 ). In the validation cohort, patients followed at the University of Chicago with a diagnosis of idiopathic PAH (SR) who agreed to participate in research were offered entry between August 2012 and March 2014. Patients consenting and providing blood samples were included in the analysis.
Definition of vasodilator-responsive PAH
PAH was defined according to standard criteria 10 . Patients were diagnosed with idiopathic or heritable PAH by experienced clinicians (IMR, ARH) and did not have evidence of connective tissue disease, liver disease or congenital heart disease on history, physical examination, laboratory or serologic testing, echocardiography or chest imaging. At the time of initial RHC all patients underwent vasodilator testing using inhaled nitric oxide at up to 40ppm as previously heritable PAH and family members were enrolled at the time of their referral to o o our r r co o oho ho hort rt rt a a as s previously described 8 . In these experiments only idiopathic and heritable PAH patients with av vai ai aila la labl bl ble e, h h hig ig igh-qu qu qua al ality peripheral blood lymphoc oc cyt yt y e es and/or high hua al lit it ity y y RNA samples were n ncl l lu uded for a ana naly ly l s sis. s. H Hea ea ealt lt lthy hy hy c con on ntr tr rol o s s s w w were e e f fr free f fr ro om m k kn know ow wn n n ca ca ard rd dio iova va asc c cul ula ar ar d dis isea ea ease se e ( ( (n= n= n=22 2 22 9 9 9 ). In h he e e va va vali li l da dati ti ion on on c co oh ho or ort, t, p pa at atie ient nt ts s s fo fo foll ll llow ow owed ed d a a at t t th th the Un Un U i iv ive er e s si ity y y o o of f f Ch Ch Chic ic cago go go w w with h h a a di di d ag ag agno no nos si sis o o of diopathic PAH AH AH ( ( (SR SR SR) ) ) wh wh who ag ag agre r r ed ed ed to to o p par ar arti ti t ci ci c pa pa pate te t i in n n re re rese se s ar ar rch ch ch w w we e ere re re o off ff ffer er ered ed ed e e ent nt ntry ry b b bet et etwe we ween en e August described 11 . VR-PAH diagnosis required a drop in mean pulmonary artery pressure (mPAP) of at least 10mmhg to <40mmHg with preserved cardiac output. VN-PAH patients met hemodynamic criteria for PAH, but did not for vasodilator responsiveness. VR-PAH patients were further required to have at least one year of therapy with calcium channel blockers. Because some patients could not tolerate CCB therapy 5 , phosphodiesterase 5 inhibitor therapy was occasionally added at the discretion of the treating physician. Patients that received endothelin receptor antagonist or prostaglandin therapy were not included as use of these medications was generally reserved for patients failing calcium channel blocker therapy clinically in our practice and suggested non-classic VR-PAH phenotype. Thirty two idiopathic and heritable VN-PAH patients were used as comparators as well as 22 healthy controls. Some of the data from these disease and healthy controls have previously been published 9 . One patient in the idiopathic PAH group in this publication was identified as VR-PAH and included in this new analysis in the VR-PAH group. All of these patients were recruited from the Vanderbilt site. Microarray was reperformed using the same platform on 2 randomly selected VN-PAH samples to confirm reproducibility over time in cultured lymphocytes.
Cultured lymphocytes
Lymphocytes culture was performed as previously described 12 . Briefly, EDTA anticoagulated venous blood was collected from patients. Lymphocytes were isolated and exposed to EpsteinBarr Virus (EBV) to induce cell immortalization. Two mL blood was diluted with 2 mL PBS, layered on top of 3 mL of Lymphocyte Separation Medium (MP Biomedicals) and centrifuged for 10 minutes at 1,000×g at room temperature. Using a Pasteur pipet, the lymphocytes were removed from the serum/Lympho Sep Media interface, washed in 10 mL PBS and then resuspended in 3 mL lymphoblast media (RPMI 1640 media containing L-glutamine, and 20%
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Microarray
RNA was isolated from lymphocytes using a Qiagen RNeasy mini kit (Valencia, Calif. 
Array Analysis
The open source software, R2.13/Bioconductor2.8, was utilized for microarray analyses.
Preprocessing of all cell files was carried out using the RMA (Robust Multi-array Average) algorithm, in which raw intensity values are background corrected, log2 transformed, and then quantile normalized. This was followed by duplicate probe removal to retain probes with higher interquartile range (IQR). Of 56,613 probe sets, 13,741 had an average expression in any group of over 7 (log base 2 units), and 5212 of these had a range of expression from maximum to minimum values of over 30%. These were used for an undirected principle components analysis (PCA). Finally, the 5212 probe list was sorted by the absolute value of the log-transformed difference between the responder and the non-responder group, with the sum of the standard deviations of each group subtracted. This returns a list sorted by minimum confidence interval fold change. The top 75 genes were used for a heat map (with hierarchical clustering), and the top 25 non sex-related were used for validation as biomarkers.
For hierarchical clustering, rows were standardized by subtracting mean and dividing by standard deviation; correlation was used as the distance metric, using the centroid linkage method. Analysis of enriched gene function groups was performed using the 2010 release of Webgestalt, using the hypergeometric test for enrichment of wither Gene Ontology consortium algorithm, in which raw intensity values are background corrected, log2 transform rm med ed ed, an a and d d th th then en quantile normalized. This was followed by duplicate probe removal to retain probes with higher n n nte te erq rq rqu ua uart rt rtil il ile e e r r rang ng ge e e (I ( QR). Of 56,613 probe sets, 1 13 1 ,741 had an av ver e e ag ge e e e ex expression in any group of f o o ove v r 7 (log b b ba a ase e e 2 2 u u unit it its) s) s), , an an and d 52 52 212 12 1 o of f f the es se e had d d a a a ra a ang ng nge e of of of e exp xp pr re ess ssio io ion fr from om om m max ax axim im imum um t t to o mi mi ini ni n mu mu mum m va va val lu lues es s o o of f ov ov ver er r 3 30% % %. Th Th Thes es ese e we we were re re u u use e ed d d fo fo for r an an n u u und nd ndi ir irec ec ecte ted d pr pr prin inc c cip pl ple e co co c mp mp mpon on onen nt t ts a a ana nal ly lys si sis PCA). Final lly ly y, , th th he e e 52 52 5212 12 2 p p pro ro robe be b l l lis is ist t wa w w s s s so so ort rt ted ed ed by by by t t the he he abs bs bsol ol olut ut ute e va va valu lue e e of of of t t the he he l l log og g-t -t tra ra rans ns nsfo fo f rmed f f categories or KEGG pathways. PCA and hierarchical clustering were performed in JMP 10, a subset of SAS.
Statistical Analysis
Continuous variables of demographic data are reported as mean ± standard deviation. The
Wilcoxon rank-sum test was used to compare differences in continuous variables between VR-PAH and VN-PAH groups. Paired measurements were compared using the Wilcoxon signedrank test. Categorical variables were compared between groups using the chi-square test or
Fisher exact test. A p value of < 0.05 was considered statistically significant. We used Wilcoxon rank-sum test to compare peripheral blood gene expression between VR-PAH and VN-PAH groups. To control the false discovery rate (FDR), the nominal p-values were corrected for multiple testing of genes. Genes that were believed to be differentially expressed at an FDR of 5% were further used to build decision trees to discriminate between VR-PAH and VN-PAH 13 .
We used rpart package and explored all the trees that can perfectly separate VR-PAH from VN-PAH with two splits. Statistical analyses were performed using Prism 5.0 software (Graph Pad Software Inc, La Jolla, CA) and R 3.0.1.
Results
Eight patients with VR-PAH were identified from the Vanderbilt cohort ( Table 1) . Functional class was unknown in one child, one patient was class II, four were class III and two were class IV. All were alive at the time of analysis. Invasive hemodynamic primary data were available for 7/8 VR-PAH patients. The single VR-PAH patient without primary data for analysis underwent diagnostic RHC 18 years prior to enrollment at a different center. Data on the 32 VN-PAH patients are presented in Table 1 . There were no significant differences in demographic groups. To control the false discovery rate (FDR), the nominal p-values were cor or rr rect ct c ed ed ed f f for or or multiple testing of genes. Genes that were believed to be differentially expressed at an FDR of 5% % w w wer er ere e fu fu furt rth h her r us us used e to build decision trees to di di disc scr riminate betwe we een V V VR R-R-PAH and VN-PAH 13 .
We We u used rpar rt t p pac ac acka ag g ge a a and nd nd e e ex xp xplo lore re red d d a a all l the tr r rees th h h t t at c c ca an an p p per r rfe fec c ctly y y s sep ep par r rat ate e e VR V VR-P -P PAH AH AH f fro o om m VN VN VN-PA PA AH H H wi wi w th th t t two wo w s sp p pli it its. s. S Sta ta ati tist s ic ic cal al l a a ana na nal ly lys se ses s s we we were e e pe pe per rf rfo o orm me med d d u us usin n ng g g P Pr Pris is ism m m 5 5.0 0 0 so so oft ftwa wa w re re re ( ( (Gr Gr rap p ph h P There was a significantly higher proportion of HPAH in VN-PAH compared with VR-PAH (p=0.01), in keeping with prior published reports 14 . There was a strong female predominance in the VN-PAH cohort (30/32) and all of the VR-PAH patients were female, which is typical of PAH 1, 15 . Of the idiopathic VN-PAH from Vanderbilt, none have BMPR2 mutation, however one did have a mutation in KCNK3 16 . While three HPAH patients included were from the same kindred, all the remaining patients were unrelated. All patients with VR-PAH patients were 
Microarray Analysis
To test the hypothesis that a different molecular etiology of VR-PAH from VN-PAH could be detected in cultured lymphocytes, we performed microarray on VR-PAH, VN-PAH and controls.
We performed principal component analysis (PCA) and found that VR-PAH patients were significantly different from VN-PAH in each of the first three principal components ( Figure 1A , 1B). Each principal component corresponds to a list of genes that are roughly coregulated, with nhibitors due to limited tolerance of high dose calcium channel blockers (gingiva va al l hy hy hype pe perp rp rpla la las si sia a = 1, peripheral edema = 1). No VR-PAH patients were treated with any other class of PAHdi ire re ect ct cted ed ed t t the he hera ra apy y. .
H He Hemodynamics were different t b b bet t tween VR-PAH AH H and nd d V V VN-PAH with
i i ign n nif i icantly hi high gh ghe e er m m mea ea an n n pu pu pulm lm lmon on nar ar ary y a a art t teria a al p p pres ssu u ure a an nd nd p p pu ul ulmo mo on na ary ry v v va as scu cu ula la lar r re resi si s st st stan an nce e e i i in n V VN VN-PA PA AH H H co co c mp mp mpar ar ared ed w w wi it ith h VR VR VR-P -PAH AH AH ( ( (p< p< p<0. 0. 0 05 05 5). ). W W Wh h hile le le n ni i itr ri ic o oxi xi xide de de h h had ad a n no o o si si s g gn gnif if fic ican an ant t t ef effe fe fec ct ct o on n n V VN VN-P -P -PA AH patients with h VR VR VR-P -P PAH AH AH h h had d d s sig ig i ni ni nifi fi fica ca ant n d d dec ec ecre re eas as ase e e in in n m m mea e n n n pu pu pulm lm mon on ona a ary y y a a art rt r er er eria ia ial l l pr pr res es essu su sure re re a and the first principal component (PC1) being the cluster of genes that explains the largest part of the variance across samples, PC2 being the gene group explaining the next most variance, et cetera.
The analysis was performed without identifying gene groups a priori; the grouping of the patient samples is thus a natural result of gene expression differences, rather than the result of selection.
PC1 consists of genes that are upregulated in VR-PAH, but not changed between VN-PAH and controls; PC2 consists of genes upregulated in VN-PAH but downregulated in VR-PAH; and PC3 consists of genes downregulated in both VR-PAH and VN-PAH. A heat map of the 75 probe sets most significantly changed between VR-PAH and VN-PAH groups is shown in Figure 1C . These data demonstrate that expression patterns in lymphocytes cultured ex vivo and without drug exposure maintained different expression patterns in VR-PAH compared with VN-PAH.
To test the hypothesis that there might be epigenetic effects of calcium channel blocker exposure on cultured lymphocytes despite ex vivo culture for several weeks, we examined the VN-PAH group for exposure to calcium channel blockers. We included only patients followed at
Vanderbilt with medication histories prior to enrollment (n=19). Of these, 9 had been exposed to calcium channel blockers at the time of enrollment. Separation of microarray data by never-or ever-exposure to calcium channel blockers did not show any differences that were attributable to this medication class and the differences from the VR-PAH persisted (Figure 2) . Thus an epigenetic effect of calcium channel blockers was unlikely to account for the observed differences of VR-PAH and VN-PAH.
For PCR follow up, we focused on comparisons between VR-PAH and VN-PAH, as the goal was to identify VR-PAH in patients with PAH, but unknown vasoreactivity. After exclusion of two genes ascribed to sex differences in the cohorts (SOX9 (EntrezGene 6662) and STEAP1 without drug exposure maintained different expression patterns in VR-PAH comp mp par ar red ed d w w wit it ith h h V VN VN-PAH.
To To To t t tes es st th h he e e h hypothesis that there might be e e e ep p pigenetic effect ct ts s of f c c ca al alcium channel blocker Vanderbilt w wit it ith h h me me medi di d ca ca cati t t on on n h h his i to to tori ri r e e es s s pr pr rio io ior r r to to to e e enr nr n ol ol ollm lm lmen ent t t (n (n (n=1 =19) 9) 9). . O O Of f f t t the he hese se se, , , 9 9 9 ha ha had d d be be been en e exposed to o f f (EntrezGene 26872)), we selected the 25 most significantly differently expressed named genes between VR-PAH and VN-PAH. Genes selected for PCR in peripheral blood are presented in Table 2 . In broad gene ontogeny categories, there were eight genes related to Rho GTPases or cytoskeleton, three transcription factors, three cell-cell adhesion factors and 11 miscellaneous genes. Of note, four genes were calcium-dependent (DAPK1, DSG2, EPDR1, TPD52) and one was activated by adenosine (P2RY5).
Peripheral Blood Gene Expression
Because isolation and culture of peripheral lymphocytes is not feasible for routine use, we sought to confirm our microarray results in peripheral blood without specific isolation of a blood compartment. We hypothesized that whole blood RNA expression would reflect the findings from microarray analysis of cultured lymphocytes that were quantitatively greatest, but might not detect the more subtle differences that can be observed in lymphocytes. We identified 8 VR-PAH and 13 VN-PAH patients with available whole blood collected via venipuncture using RNA preservation tubes and isolated RNA. qPCR was performed for the genes in Table 2 . After correction for multiple comparisons, we found statistically different expression in 13/25 genes at a FDR level of 5% as listed in Table 3 . Of the genes statistically different between the two groups, five were related to rho GTPase and cytoskeleton, two were cell-cell adhesion factors, two were developmental genes, one transcription factor and three were of miscellaneous function.
Three of these genes were known to be calcium dependent or activated by adenosine (EPDR1,
DSG2 and TPD52).

Validation in an External Cohort
We sought to validate our whole blood RNA expression findings in a second cohort of patients followed at the University of Chicago (Supplemental Table 1 ). Whole blood from five patients compartment. We hypothesized that whole blood RNA expression would reflect t th t the e e fi fi ind nd ndin in ings gs gs from microarray analysis of cultured lymphocytes that were quantitatively greatest, but might no de ete te ect ct ct t t the he he m m mo ore su su sub bt btle differences that can be obs bs bser erv ved in lymphoc oc ocytes es s. . W W We identified 8 VR-
PA PAH H H and 13 V VN N N-P PA PAH H H p pa pati ti tien en ents ts s w wit it ith h h av av va ai ilab bl le whol ole e bl bl lo oo ood d co o oll lle ect ted ed v via i i v ven en nip ip pun unc ct c ur ur ure e us us usin in ing g RN RN NA A A pr pr pres eser er erva v vati tio on on t tub ub bes es s a and nd i isol ol olat at ated ed ed R R RNA NA NA. . qP P PCR CR CR w w was s s p p per er erf fo form rm rme ed ed f f for or o t t the he he g gen en enes es es i in n n T T Tab b ble e 2 2. . Af Af Afte ter correction for or r m m mul ul lti ti tipl pl p e e e co c c mp mp mpar a a is is son on o s, s, s, w w we e e fo fo foun un und d d st st stat at atis is sti ti t ca a all ll lly y y di di d ff ff ffer er eren en nt t t ex ex expr pr pres es essi si s on on on i i in n n 13 13 13/2 / 5 genes at t with confirmed long-term response to calcium channel blockers and 6 VN-PAH patients recruited separately was collected in RNA isolation tubes and sent to our center. RNA was isolated and PCR performed for the 25 most differentially expressed genes found in the discovery cohort. Figure 3 and Supplemental Table 2 show qPCR results of the 13 significantly different genes from the primary analysis in the Vanderbilt cohort in both our cohort and the University of Chicago and control patients. In general there was broad concordance in findings of differentially expressed genes in the two VR-PAH cohorts, but lower numbers in the University of Chicago cohort may have reduced statistical power in that group. Gene expression was suppressed in VR-PAH compared with VN-PAH in 8/13 genes and only upregulated in 5/13
genes compared with VN-PAH.
Development and Validation of a Peripheral Blood-Based RNA Expression Model to Detect
VR-PAH
We sought to use the differentially expressed genes identified above to develop a peripheral blood qPCR test to differentiate VR-PAH from VN-PAH. We thus constructed decision trees using expression levels of significantly differently expressed genes to discriminate between the two types of PAH. The University of Chicago cohort was used to validate the strength of the proposed decision trees. We found that no more than two genes were required to distinguish VR- 
Development and Validation of a Peripheral Blood-Based RNA Expression Model to Detect VR VR R-P -P -PAH AH AH
We We s sought to u use se e t t the e d dif f ffe fe fer re rent nt nti ia iall lly y y e ex exp pr pre esse ed gen ne es s iden en enti tifi fi fied Table 4 . These data demonstrate that mRNA expression patterns in peripheral blood of selected genes can be used to differentiate VN-PAH from VR-PAH.
Discussion
We have used ex vivo cultured lymphocytes from VR-and VN-PAH patients to identify genes differentially expressed in these two distinct PAH treatment phenotypes. We then used these expression differences to develop and validate a whole blood RNA expression-based profile that distinguishes VR-PAH from VN-PAH. These data show that VR-PAH and VN-PAH likely have a different molecular etiology and the resultant gene expression differences can be reliably detected in the peripheral blood. These studies serve as proof of the concept that PAH treatment response phenotypes may be identified in peripheral blood and these markers could be used prospectively to predict response to therapy, so-called personalized medicine. Extension of this approach to other classes of PAH therapies may be useful.
Treatment of PAH has advanced significantly in the past several decades with many recent publications showing improved survival compared with historical controls 2, 17, 18 .
Nonetheless, there remains substantial morbidity and mortality; delay of therapy and inability to identify appropriate therapy remain important challenges for practitioners treating PAH 19 . We used VR-PAH as a readily recognized, clinically distinct phenotype with improved survival (5-year survival 98% vs. 48% 3 ) and well-defined response to therapy 3, 5 as a tool to show proof of the concept that peripheral blood RNA expression can identify patients likely to respond to specific PAH-directed therapies. If validated prospectively, these profiles may become the first distinguishes VR-PAH from VN-PAH. These data show that VR-PAH and VN--PA PA PAH H H li li like ke kely ly ly h h hav a e a different molecular etiology and the resultant gene expression differences can be reliably de ete te ect ct cted ed ed i i in n n th th the pe pe er ri riph p eral blood. These studies se se serv rve e as proof of th th he co onc nc ncep e t that PAH treatment e esp p pon o se pheno noty ty yp p pes s ma ma may y be be be i i id de dent nt tif if fie ied d d i in n pe e eri i iphe er ra a al blo lo lood od an nd nd t the he ese e m m ma ar rke ke ers rs rs c cou ould ld ld b b be e us us s d ed ed pr pros os ospe pe pect ct c iv ivel el ely y y to to pr re redi dict ct r res espo po ons ns se e e to to to t the he era ra apy py py, , so so o-c -ca a all le led d d pe pe ers rs rson on nal al a iz iz zed ed d m m me ed edi ic ici ine ne ne. Ex Ex E te te ten n nsio o on n of of t t thi i is s approach to ot ot the he her r cl cl clas as asse se ses of of of PA PA PAH H H th th her e e ap ap apie ie es s ma ma may y y be be be u u use sefu fu ful. l. . companion diagnostic test for identifying the most appropriate treatment of PAH. Availability of a blood test would also help assure that VR-PAH patients are not missed, which can have tragic consequences.
Use of cultured lymphocytes in development of potential qPCR targets provided several advantages in this study. First, they were cultured outside of the patients for several weeks, thus removing any potential influence of calcium channel blockers as demonstrated in Figure 2 , PAH directed therapy or other environmental effects. Second, cultured lymphocytes remove much of the well-described variability in whole blood RNA expression profiles that may reflect day to day variability in inflammation, dietary or environmental exposures. Thus they can provide greater insight into more subtle underlying molecular differences in patient phenotypes and this has been used as an advantage of these cell lines in other medical diseases 20 . We found significant differences in gene expression profiles using microarray analysis in VR-PAH and VN-PAH that required two principal components to fully separate the groups. Major gene ontology groups that were different included cytoskeletal/Rho GTPase genes, cell-cell adhesion genes, transcription factors and developmental pathways, pathways that are known to be associated with PAH. The identification of several calcium-dependent genes in the most differentially expressed group using an unbiased, discovery-based approach could not be attributed to drug effect given the long culture period of the lymphocytes outside of drug exposure and may suggest that alterations in calcium-dependent cell-cell adhesion plays a role in VR-PAH.
We used an unbiased discovery approach to identify differentially expressed genes in cultured lymphocytes and did identify several gene ontology groups previously published to play a role in PAH. Specifically, cytoskeletal genes, ion channels and developmental pathways have greater insight into more subtle underlying molecular differences in patient pheno no oty ty ype pes s an an and d d t th thi is has been used as an advantage of these cell lines in other medical diseases 20 . We found i ign gn nif if ific ic ican an nt t t d di dif ffer er ren en enc ces in gene expression profile e es s s u u using microarr ray ay a ana na aly ly lysis in VR-PAH and VN VN VN-P -PAH that t re requ qu uir red ed ed t t two wo wo p p pri ri rin nci cipa pa pal l c com m mpo o one e ents s to o o fu u ull ll ly y s se ep pa para ra ate e t the he g gr ro oup up ps s. . M Maj aj ajor or or g gen n ne e on nto to tolo lo logy gy gy g g gro ro roup ups s th h hat at w w we er ere e di di iff ff f er er ren en ent t t i inc nc clu u ude de ded d d cy cy cyto to osk k kel e et et e al al al/R /R /Rho ho o G G GTP TP Pa a a t t t se se e g gen enes es es, , ce ce c ll ll l-c -c cell l l ad d dhe hes s sio on on genes, transcr cr rip ip ipti ti t on on on f fac ac a to to t rs s s a a and nd n d d dev ev evel el e op op pme me ment nt n a a al l pa pa path th hwa wa w ys ys ys, , pa pa path th thwa wa ways ys s t tha ha hat t t ar ar are e e kn kn now ow own n n to to to be been well described to play a role in human and animal models of PAH 9, 16, 21, 22 . VR-PAH patients were markedly different from VN-PAH patients in these pathways, some to greater degree than others, but all appeared to be different. This may lend insight into a different molecular etiology of VR-PAH. The identification of several calcium-and adenosine-dependent genes may be purely coincidence or may reflect the potent effect of many vasodilators in the treatment of VR-PAH. Although this study did not explore how the differentially expressed genes may contribute to phenotypes of PAH treatment, the strong differences in several genes' expression is provocative. DSG2 or desmoglein-2 is a desmosomal cadherin that is known to be highly expressed in cardiac tissue [23] [24] [25] and has been shown to underlie some cases of arrhythmogenic right ventricular dysplasia 23, 24, 26 . Although the mechanism by which DSG2 mutations causes this disease are presently incompletely understood, alterations in Wnt/ -catenin signaling may play a role 27 , and this pathway is similarly implicated in idiopathic and heritable PAH 28 . RHOQ also strongly differentiated VR-PAH from VN-PAH. This cytoskeletal gene facilitates protein transport and has been shown to be important in insulin-mediated signaling 29 ,
another pathway of importance in PAH [30] [31] [32] . Of note, only EPDR1, UCHL1, DSG2, SCD5 and P2RY5 expression levels were elevated in VR-PAH compared with VN-PAH, and gene expression levels were more commonly suppressed in VR-PAH which may reflect underlying disease mechanism. Of note, the methodology we used to identify these genes used an unbiased approach and did not identify many genes previously found to be important in pathogenesis of PAH [33] [34] [35] . This methodology does not discredit their role in pulmonary hypertension, but this approach did not identify these genes to be the within the top 25 most differentially expressed. If these molecules are functionally important in VR-PAH, they may explain how several different compounds can produce vasodilation in this phenotype.
arrhythmogenic right ventricular dysplasia 23, 24, 26 . Although the mechanism by w wh whic ic ch h DS DS DSG2 G2 G2 types. Nonetheless, we were able to detect clear differences in PAH treatment phenotype in our cultured lymphocytes, including cell-cell adhesion factors. This study was designed to identify a peripheral blood signature of VR-PAH, but cannot by nature lend insight into how the differentially expressed genes may or may not contribute to disease pathogenesis in each treatment phenotype. Further study will be needed to understand the mechanistic implications of This study has some limitations. The numbers of VR-PAH are low for se ev v vera ra r l l re reas as ason on ons. s.
First, in order to be most stringent in definition of phenotype, we excluded any patient being r rea ea ate te ted d d wi wi with th th e e end dot ot oth he helin receptor antagonists or p p pro ro r s st tacyclins as th h hes e e e pa pa pat ti tients may have a d di diff f fer e ent, or in nte term rm rmed ed dia i i te te e p p phe he hen no noty type pe pe. T Th Thi is le e eft t us w w wi ith on on only ly y f fe em ema al ale e p pat atie i i n n nts, s, a an nd nd t the he hese se s r r res s sul u ults ts s m m may no not t t be be be a app pp ppli li lica c cabl ble e e t to o m m mal le e p pati ti tien en nts ts ts. Se Se S c co ond nd nd, , VR VR VR-P -PAH AH AH a a acc c cou ou ount nt ts s s fo fo or 5-5-5-10 10 0% % % of of f a all ll ll i idi di diop op opat t thi hic c c PA PA AH H H which is itsel elf f f ve ve v ry ry ry r r rar ar re. e. e T The he he u use se se o o of f f a a a se se seco co ond nd nd, , se se epa pa para ra rate te t c c coh oh ohor or ort t fo fo for r r va a ali li lida da dati ti tion on on t tes es ste te ted d d in in in a a different the identified genes.
In conclusion, we have identified an RNA expression profile in peripheral blood that can identify VR-PAH patients from VN-PAH patients. These data may serve as a proof of concept that peripheral blood RNA expression profiles can be used to identify optimal drug treatment in PAH. Further study is warranted to determine if this experimental model may be applied to understanding mechanisms of forms of pulmonary hypertension (WHO Groups 2-5) or whether it may be used to identify optimal treatment a priori in PAH. 
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